Products

Pain Management

Gastroenterology

Nephrology

Oncology

Consumer Health

CM139

CM139 is an affordable calcium acetate + magnesium carbonate phosphate binder for the control of serum phosphorus in patients with ESRD.

Hyperphosphatemia in ESRD Patients

Hyperphosphatemia in patients with end-stage renal disease (ESRD) can lead to secondary hyperparathyroidism, renal osteodystrophy, soft tissue mineralization and the progression of renal failure – all of which significantly increase patient mortality and morbidity.

As such, phosphorus control is critical to the quality of care for dialysis patients.

Treatment with Phosphate Binders

The treatment of hyperphosphatemia usually involves dialysis in conjunction with dietary phosphate restrictions and intake of phosphate binders. Phosphate binders are generally classified as calcium-based and non-calcium-based drugs.

Calcium acetate is an intestinal, calcium-based phosphate binder that is roughly three times more effective than calcium carbonate in controlling serum phosphate. When taken with meals, calcium acetate binds with dietary phosphate to form insoluble calcium phosphate, which is subsequently excreted in the feces. By controlling phosphorus absorption from the gastrointestinal tract, calcium acetate controls the serum phosphorus level.

For patients with higher-than normal serum calcium levels, magnesium carbonate, an affordable non-calcium-based phosphate binder, can be combined with calcium acetate to slow the calcification process.

CM139

CM139 is a calcium acetate product for binding phosphate in ESRD patients, combined with magnesium carbonate to slow the calcification process